Affect lability and Gastrointestinal inflammation

Summary:

Gastrointestinal inflammation is reported only by a few people with Affect lability.

The study analyzes which people have Gastrointestinal inflammation with Affect lability. It is created by eHealthMe based on 2 people who have Gastrointestinal inflammation and Affect lability from the Food and Drug Administration (FDA), and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 20, 2022

2 people who have Affect Lability and Gastrointestinal Inflammation are studied.


What is Affect lability?

Affect lability (emotional incontinence) is found to be associated with 1,169 drugs and 735 conditions by eHealthMe.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 774 drugs and 512 conditions by eHealthMe.

Number of Gastrointestinal inflammation in Affect lability reports submitted per year:

Would you have Gastrointestinal inflammation when you have Affect lability?

Gender of people who have Affect Lability and experienced Gastrointestinal Inflammation *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Affect Lability and experienced Gastrointestinal Inflammation *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common co-existing conditions for these people *:

  1. Memory Loss: 2 people, 100.00%
  2. High Blood Pressure: 2 people, 100.00%
  3. Depression: 2 people, 100.00%
  4. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 2 people, 100.00%
  5. Abdominal Discomfort: 2 people, 100.00%

Common drugs taken by these people *:

  1. Prilosec: 2 people, 100.00%
  2. Norvasc: 2 people, 100.00%
  3. Namenda: 2 people, 100.00%
  4. Klor-Con: 2 people, 100.00%
  5. Fluoxetine: 2 people, 100.00%
  6. Aspirin: 2 people, 100.00%
  7. Xanax: 1 person, 50.00%
  8. Mirapex: 1 person, 50.00%
  9. Humira: 1 person, 50.00%
  10. Estrogel: 1 person, 50.00%

Common symptoms for these people *:

  1. Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 100.00%
  2. Oedema Peripheral (superficial swelling): 2 people, 100.00%
  3. Nodule (a small rock or mineral cluster): 2 people, 100.00%
  4. Erythema Nodosum (skin inflammation that results in reddish, painful, tender lumps most commonly located in the front of the legs below): 2 people, 100.00%
  5. Diarrhea: 2 people, 100.00%
  6. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 2 people, 100.00%
  7. Abdominal Tenderness: 2 people, 100.00%
  8. Drug Ineffective: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Gastrointestinal inflammation:

Common drugs associated with Gastrointestinal inflammation:

All the drugs that are associated with Gastrointestinal inflammation:

Common conditions associated with Gastrointestinal inflammation:

All the conditions that are associated with Gastrointestinal inflammation:

How the study uses the data?

The study is based on Gastrointestinal inflammation and Affect lability, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: